SecBot SecBot
SECBOTREPLAY Home › Report › NVAX

NVAX · Novavax reported strong financial results for Q4 and full year 2025,…

NOVAVAX INC · 8-K filed Feb 26, 2026 at 08:02 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 26, 2026 at 08:02 ET

Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147 million in Q4 and $1.12 billion for the full year, driven by Sanofi milestones and licensing revenue. The company also announced a major non-exclusive license agreement with Pfizer for its Matrix-M adjuvant technology, receiving a $30 million upfront payment and potential for up to $500 million in milestones. Despite a cash balance decline to $751 million, Novavax secured a $330 million credit facility and guided to $230-$270 million in adjusted revenue for 2026.

  • Q4 2025 revenue: $147 million (+67% YoY)
  • Full year 2025 revenue: $1.123 billion (+65% YoY)
  • Net income: $18 million in Q4 2025 vs. $81 million loss in Q4 2024
  • Pfizer agreement: $30 million upfront, up to $500 million in milestones, and high-mid-single digit royalties

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access